The additive contains viable spores of two strains of Bacillus amyloliquefaciens and a single strain of Bacillus subtilis and is intended to be used with pigs for fattening and minor porcine species at a minimum inclusion level of 1.5 9 10 8 colony forming units (CFU)/kg complete feedingstuffs. The two bacterial species are considered suitable for the qualified presumption of safety (QPS) approach to safety assessment, which requires the identity of the strains to be established and evidence that they lack toxigenic potential and acquired antimicrobial resistance determinants for antibiotics of human and veterinary importance. The identity of the three active agents is established and the lack of toxigenic potential confirmed. The two B. amyloliquefaciens strains do not show resistance to relevant antibiotics, and are presumed safe for the target species, consumers and the environment. The B. subtilis strain showed a low level of resistance to streptomycin, for which acquired resistance genes were not identified. Therefore, it also complies with the QPS qualifications and is presumed safe for the target species, consumer and the environment. Since no other component give rise to concerns, Cinergy ® Life B3 HiCon is also considered safe for the target species, consumers and the environment. In the absence of data, no conclusions can be made on the skin or eye irritancy or the potential for dermal sensitisation of the additive. Owing to the proteinaceous nature of the active agents, the additive is considered a potential respiratory sensitiser. However, the low dusting potential makes it unlikely that additive poses a risk for the respiratory system. Cinergy ® Life B3 HiCon showed a potential to improve the feed to gain ratio in pigs for fattening given the additive at a minimum inclusion level of 1.5 9 10 8 CFU/kg complete feed. This conclusion is extrapolated to minor porcine species at the same application rate and for an equivalent growth phase.
establishes the rules governing the Community authorisation of additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an application in accordance with Article 7.
The European Commission received a request from Cargill Incorporated, represented By Provimi Holding BV 2 for authorisation of the product Cinergy ® Life B3 HiCon (Bacillus amyloliquefaciens NRRL B-50508, B. amyloliquefaciens NRRL B-50509 and Bacillus subtilis NRRL B-50510) when used as a feed additive for pigs for fattening and minor porcine species (category: zootechnical additive; functional group: gut flora stabiliser).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application to the European Food Safety Authority (EFSA) as an application under Article 4(1) (authorisation of a feed additive or new use of a feed additive). The particulars and documents in support of the application were considered valid by EFSA as of 8 January 2018.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and documents submitted by the applicant, shall undertake an assessment in order to determine whether the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the safety for the target animals, consumer, user and the environment and on the efficacy of the product Cinergy ® Life B3 HiCon (Bacillus amyloliquefaciens NRRL B-50508, B. amyloliquefaciens NRRL B-50509 and Bacillus subtilis NRRL B-50510), when used under the proposed conditions of use (see Section 3.1.4).
Additional information
The additive Cinergy ® Life B3 HiCon has not been previously authorised as a feed additive in the EU.
2
Data and methodologies
Data
The present assessment is based on data submitted by the applicant in the form of a technical dossier 3 in support of the authorisation request for the use of active agent as a feed additive. The technical dossier was prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003, Regulation (EC) No 429/2008 4 and the applicable EFSA guidance documents.
EFSA has verified the European Union Reference Laboratory (EURL) report as it relates to the methods used for the control of the active agent in animal feed. The Executive Summary of the EURL report can be found in Annex A. 5
Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efficacy of Cinergy ® Life B3 HiCon is in line with the principles laid down in Regulation ( 
Assessment
The additive is a preparation containing viable spores of two strains of B. amyloliquefaciens and a single strain of B. subtilis intended to be used in feed for pigs for fattening and minor porcine species as a zootechnical additive to improve performance.
Characterisation

Characterisation of the active agents
All strains are deposited with the United States Department of Agriculture Agricultural Research Culture Collection (NRRL Collection) with the accession numbers NRRL B-50508 and NRRL 50509 for the two B. amyloliquefaciens strains and NRRL B-50510 for the B. subtilis. 7 None of the strains have been genetically modified. 8 Randomly amplified polymorphic DNA (RAPD) PCR genotyping analysis supported the differentiation between the additive strains and between other similar strains.
No cytotoxic effects were detected in any of the strains. (Ohmiya et al., 1989; Kunst et al., 1997) 
Characterisation of the additive
The final product is a powder with a minimum specified count of Bacillus spp. is 2.5 9 10 9 CFU/g additive with the three strains contributing approximately in equal numbers. specification was demonstrated in five batches of the additive. The counts given for the individual strains are the same for all batches Three batches of the additive were analysed for heavy metals and arsenic, dioxins and dioxin-like polychlorinated biphenyls (PCBs) and mycotoxins. Lead, cadmium and arsenic were detected at mean concentrations of 1.8, 0.16 and 0.31 mg/kg additive respectively, while mercury was not detected (limit of quantification (LOQ) < 0.01 mg/kg additive). 16 The mean upper bound value for the sum of dioxins and dioxin-like PCBs was 0.09 ng WHO-PCDD/F-PCB-TEQ/kg additive. These values are substantially below the maximum levels permitted in feed materials and do not raise concerns. None of the mycotoxins included in the analysis could be detected (LOQ total aflatoxins < 0.05 lg/kg, total fumonisins < 30 lg/kg, total HT-2 Toxin < 50 lg/kg, total T-2 toxin < 5 lg/kg zearalenone < 25 lg/kg, ochratoxin < 5 lg/kg and vomitoxin < 50 lg/kg). The same three batches were examined for evidence of microbial contamination. Coliforms, Escherichia coli, Bacillus cereus and Staphylococcus aureus were below the detection limits (< 10 CFU/g additive) and no Listeria or Salmonella species could be isolated from 25 g or 50 g of the additive, respectively.
Sterile culture filtrate obtained from growth of three batches of the additive did not produce zones of clearing in lawn cultures of a number of test bacterial species indicating that the strains do not produce extracellular antibacterial activity. 17 Particle size distribution using laser diffraction 18 and dusting potential by the Stauber-Heubach method were measured in three batches of additive. The mean particle size was approximately 430 lm with only around 2% (v/v) of particles with diameters < 100 and 0.7% < 10 lm. The dusting potential reflected both the particle size distribution and the inclusion of an unspecified mineral oil as binder and gave a mean value of 0.2 g/m 3 . 19
Stability and homogeneity
The shelf-life of the additive was determined by monitoring three batches stored at either 25°C/ 60% relative humidity (RH) or 40°C/75% RH for a period of 24 months. 20 Essentially no reduction in total Bacillus count was observed at either temperature.
Three batches of the additive were individually mixed into a commercial vitamin-mineral premix (containing choline chloride) at a concentration of 1 9 10 11 CFU/kg premix and samples taken and stored in a sealed container for 6 months at 25°C. 21 Results showed that numbers of bacilli in the in the vitamin-mineral premix after 6 months was within AE0.5 log 10 CFU/g of the time zero count.
Stability in complete feed was investigated using three batches of the additive incorporated into a typical mash feed for pigs (maize, barley and soybean) and into a pelleted feed of the same composition (pelleting conditions 95°C for 30 s). 22 Samples of the mash and pelleted feed were placed in sealed foil bags and stored for up to 3 months at 25°C. Counts of total bacilli were made at the start and after 1 and 3 months. Essentially no reduction in total counts was seen in either the mash feed or the pelleted feed after pelleting. The effect of pelleting itself, obtained by comparison of the initial counts of the mash and pelleted feed, was small and less than 0.5 log 10 difference.
A total of 10 subsamples were taken from the mash feed after 10 min mixing and analysed for total bacilli counts. 22 Based on the ten samples, the coefficient of variation was 1%, demonstrating homogeneous mixing.
In the absence of any significant reduction in counts in any of the above studies, it is considered unnecessary to monitor individual strains.
Conditions of use
The product is proposed for use in feed for pigs for fattening and minor porcine species at a minimum inclusion level of 1.5 9 10 8 CFU/kg complete feedingstuffs.
Safety
Safety for target animals, consumers and environment
The bacterial species B. subtilis and B. amyloliquefaciens are considered by EFSA to be suitable for the qualified presumption of safety (QPS) approach to safety assessment (EFSA, 2007; EFSA BIOHAZ Panel, 2017) . This approach requires the identity of the strains to be conclusively established and evidence that the strains lack toxigenic potential and do not show acquired antimicrobial resistance determinants for antibiotics of human and veterinary importance.
In the view of the FEEDAP Panel, the identity of the three active agents is established and the lack of toxigenic potential confirmed. The two B. amyloliquefaciens strains do not show resistance to antibiotics of human and veterinary importance, and therefore, are presumed safe for the target species, consumers of products derived from animals fed the additive and the environment. The third strain, B. subtilis NRRL B-50510, showed a low level of resistance to streptomycin, for which acquired resistance genes were not identified. Therefore, it also complies with the QPS qualifications and is presumed safe for the target species, consumer and the environment. Since the other components of the additive do not give rise to concerns, Cinergy ® Life B3 HiCon is also considered safe for the target species, consumer and the environment.
Safety for the user
No studies, other than those relating to dust formation, were provided. In the absence of data no conclusions on skin or eye irritancy or on dermal sensitisation can be made.
Owing to the proteinaceous nature of the active agents, the additive is considered a potential respiratory sensitiser. The particle size distribution and dusting potential make it unlikely that additive represents a respiratory hazard.
Efficacy
Efficacy for pigs for fattening
Four efficacy studies were performed, two in the same Member State and location and two in a non-EU country.
The first two trials were made at the same location using a common design and the same breed of pig (Table 1) but separated by a 3-month period. The 96 animals (equal numbers of male and female) in each trial were distributed according to body weight at the start to a total of 32 pens each containing three animals of the same sex. Sixteen pens (eight male and eight female pens) were allocated to each of the two treatmentsa control group fed the basal diet and a test group given the basal diet supplemented with 1.5 9 10 8 CFU bacilli/kg feed. All feeds were analysed for the presence of bacilli, but results were confused by a high background count. Animals were fed mash diets containing maize, maize dry distillers grain with solubles (DDGs), wheat middlings and soybean meal in three phases. The duration of the trials was 96 days for trial 1 23 and 97 days for trial 2. 24 The parameters recorded were body weight and total pen feed intake at days 0, 42 and the end of the trial. From these data average daily weight gain, average daily feed intake and feed to gain ratio were calculated. At the end of the trials all pigs were slaughtered and carcasses evaluated. Data were analysed by analysis of variance (ANOVA) with the pen as the experimental unit. For performance data, the model used included dietary treatment, sex, block and the interaction between treatment and sex as main effects, while for carcass data the model included dietary treatment, sex and the interaction. Group means were compared using the Dunnett's test.
In the third trial, 120 pigs (Table 1) were distributed in a randomised block design across 30 pens, with 15 pens (8 of females and 7 of male barrows) per treatment with four pigs in each pen. 25 The two treatment groups were a control group given mash feeds in three phases based on maize, maize DDGs and soybean meal and a test group fed the same basal diets supplemented with the additive at 1.5 9 10 8 CFU/kg diet (confirmed for the test group). The duration of the trial was 111 days. Body weight measurement and feed consumption per pen were made every 3 weeks or on change of diet and from these data average daily gain, average daily feed intake and feed to gain ratio calculated. Four male and four females per treatment were removed from the trial for a digestibility study (not reported) and the data arising from the pens from which pigs were removed (2, 3, 17 and 12) were excluded from the analysis of performance (in the last 2 phases). At the end of the trial 100 pigs were slaughtered and carcass composition assessed. Data were analysed by ANOVA with the pen as the experimental unit for performance measurements. For carcass composition data, the individual pig was used as the experimental unit. For all data, the model included treatment and sex as a fixed effect, and the interaction of treatment 9 sex.
The fourth trial involved 56 pigs (Table 1) which were distributed in a randomised block design across 14 pens with seven pens per treatment with four pigs (2 female and 2 male barrows) in each pen. 26 Pigs were introduced into the trial in three batches at weekly intervals to ensure approximately equal start weights. The two treatment groups were a control group given mash feeds in three phases based on maize, maize DDGs and soybean meal and a test group fed the same basal diets supplemented with the additive at 1.5 9 10 8 CFU/kg diet (confirmed for the test group). The overall duration of the trial was 109 days but, because of the different start dates, the average duration for individual animals ranged between 84 and 92 days for the control group and 84 and 93 days for the treatment group. It is presumed that individual animals were retained on trial until reaching a body weight of approximately 120 kg. Body weight and feed consumption was recorded at the start, at each dietary interval and at the end of the trial and from these data average daily gain, average daily feed intake and feed to gain ratio calculated. The data were analysed by ANOVA with the pen as the experimental unit. Initial bodyweight was included as a covariate. Group means were compared using the Tukey's test. Pietrain 9 (Landrace 9 Yorkshire) 96 16 9 3 0 1.5 9 10 8 180/2.1/6.4 9 10 6 0.7/0.4/1.4 9 10 8 (maize, maize DDGs, wheat middlings and soybean) mash 2 (97)
Pietrain 9 (Landrace 9 Yorkshire) 96 16 9 3 0 1.5 9 10 8 4.0/160/4.0 9 10 6 0.6/0.3/0.6 9 10 8 (maize, maize DDGs, wheat middlings and soybean) mash 3 (111) PIC Genetiporc 6.0 9 Genetiporc F25 120 15 9 4 0 1.5 9 10 8 4.5/8.0/1.3 9 10 6 1.2/1.4/1.0 9 10 8 (maize, maize DDGs and soybean meal) mash 4 (109) (Yorkshire 9 Landrace) 9 Duroc; Yorkshire 9 Duroc 56 7 9 4 0 1.5 9 10 8 6.3/1.2/1.0 9 10 6 0.2/2.0/0.3 9 10 8 (maize, maize DDGs and soybean meal) mash CFU: colony forming unit. The Panel notes the abnormal high Bacilli counts in one control diet sample in studies 1 and 2. The applicant justified these values by a high background contamination and subjected all feed samples to confirmation of the presence of the active agents. All control feed samples proved negative and the treated feeds proved positive. Positive refers to a sample in which the majority of the colonies have a morphology similar to that of the three added Cinergy Life B3 HiCon Bacillus strains. The FEEDAP Panel does not consider this to be of concern.
No mortalities occurred in either of the first two trials, but in trial 2 two animals from the Cinergy group had to be withdrawn because of ill-health. There were no significant differences in growth or feed intake in either trial but, in both cases, there was a significant improvement in feed to gain ratio ( Table 2) . No significant effects were seen on carcass composition in trial 1 (liveweight, hot carcass, killing out percentage, % offals, % lean meat). In trial 2, the backfat depth was significantly reduced (15.1 mm vs. 16.7 mm) and lean meat percentage significantly increased (61.5% vs. 59.9%) in the treated group compared to control values.
In the third study, two pigs died during the trial and two were removed (one from each treatment group in both cases) because of enteric disease. Overall, there were no significant differences between the control and treated groups in performance (Table 2) or carcass composition (not reported).
In the last study, no mortalities occurred and no animals were removed from the trial. Feed intake was significantly lower in the treated group compared to the control animals without an effect on final body weight (Table 2) . This led to an improved feed to gain ratio, although the difference did not reach significance.
Since significant effects were observed in two studies only, the applicant performed an analysis pooling the data shown in Table 2 , including the effect of the treatment, study and their interaction. No interactions were found between treatment and study, and a significant difference was found for feed to gain ratio between the treatments (control 2.50 vs. additive 2.43, p = 0.019). 27
Conclusions on efficacy
Two of the four individual studies showed a significant improvement in feed to gain ratio in favour of the additive. Pooling of the data from the four studies showed a potential of the additive at a minimum inclusion level of 1.5 9 10 8 CFU/kg complete feed to improve the feed to gain ratio of pigs for fattening.
Efficacy for minor porcine species
Since a potential to improve the feed to gain ratio in pigs for fattening given the additive at the recommended inclusion level of 1.5 9 10 8 CFU/kg complete feed was shown, the same conclusion can be extrapolated to minor porcine species at the same minimum application rate and for an equivalent growth phase.
Post-market monitoring
The FEEDAP Panel considers that there is no need for specific requirements for a post-market monitoring plan other than those established in the Feed Hygiene Regulation 28 and Good Manufacturing Practice.
Conclusions
The three active agents comprising the additive (B. amyloliquefaciens NRRL B-50508 and B-50509 and B. subtilis NRRL B-50510) meet the requirements of the QPS approach to safety assessment and are presumed safe for the target animals, consumers of products derived from animals fed the additive and the environment. Since the other components of the additive do not give rise to concerns, Cinergy ® Life B3 HiCon is also considered safe for the target species, consumer and the environment.
In the absence of data, no conclusions on skin or eye irritancy or on the potential for dermal sensitisation can be made. Owing to the proteinaceous nature of the active agents, the additive is considered a potential respiratory sensitiser. However, the low dusting potential makes it unlikely that additive poses a risk for the respiratory system. Cinergy ® Life B3 HiCon showed a potential to improve the feed to gain ratio in pigs for fattening at the minimum inclusion level of 1.5 9 10 8 CFU/kg complete feed. This conclusion is extrapolated to minor porcine species at the same application rate and for an equivalent growth phase. 
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